Issue 65, 2020

Clustered nanobody–drug conjugates for targeted cancer therapy

Abstract

A clustered Nb–drug conjugate (cNDC@PEG) was designed using anti-EGFR Nb to specifically deliver Pt(IV) prodrugs to tumors. cNDC@PEG efficiently targets EGFR positive tumor cells, and the clustered cNDC@PEG is more efficient in inhibiting tumor growth in vivo than the monomeric NDC. This work provides a novel strategy for the construction of a multi-valent NDC using dendrimers.

Graphical abstract: Clustered nanobody–drug conjugates for targeted cancer therapy

Supplementary files

Article information

Article type
Communication
Submitted
11 May 2020
Accepted
19 Jun 2020
First published
16 Jul 2020

Chem. Commun., 2020,56, 9344-9347

Clustered nanobody–drug conjugates for targeted cancer therapy

T. Wu, M. Liu, H. Huang, Y. Sheng, H. Xiao and Y. Liu, Chem. Commun., 2020, 56, 9344 DOI: 10.1039/D0CC03396K

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements